Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v22-FR | Version v10-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2024-03-28 | 2023-08-18 |
| Drug Identification Number | 02244475 | 02244475 |
| Brand name | DIPYRIDAMOLE INJECTION, USP | DIPYRIDAMOLE INJECTION, USP |
| Common or Proper name | DIPYRIDAMOLE INJECTION, USP | DIPYRIDAMOLE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | DIPYRIDAMOLE | DIPYRIDAMOLE |
| Strength(s) | 5MG | 5MG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10 mL | 10 mL |
| ATC code | B01AC | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-07-01 | 2023-07-01 |
| Actual start date | 2023-08-23 | 2023-08-23 |
| Estimated end date | 2024-06-30 | 2023-09-30 |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | Yes | Yes |
| Company comments | Please be advised that this product is on 100% allocation. | Fresenius Kabi Canada is pleased to advise that our Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL will be available at all distribution centres by August 23, 2023. Once available, this product will be placed on allocation. Allocations will be made available on a weekly basis and are built using 100% historical monthly demand. We are working diligently to ensure equitable distribution of the limited product we have available at this time and appreciate your patience and understanding during this supply challenge. Please see communication for further details. |
| Health Canada comments |